782 related articles for article (PubMed ID: 7555511)
1. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
Cusi K; Cunningham GR; Comstock JP
Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
[TBL] [Abstract][Full Text] [Related]
2. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE
Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
[TBL] [Abstract][Full Text] [Related]
5. Comparison of combined therapies in treatment of secondary failure to glyburide.
Trischitta V; Italia S; Mazzarino S; Buscema M; Rabuazzo AM; Sangiorgio L; Squatrito S; Vigneri R
Diabetes Care; 1992 Apr; 15(4):539-42. PubMed ID: 1499473
[TBL] [Abstract][Full Text] [Related]
6. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Clauson P; Karlander S; Steen L; Efendic S
Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
[TBL] [Abstract][Full Text] [Related]
7. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Riddle MC; Schneider J
Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
[TBL] [Abstract][Full Text] [Related]
8. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different insulin regimens in elderly patients with NIDDM.
Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
[TBL] [Abstract][Full Text] [Related]
10. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
[TBL] [Abstract][Full Text] [Related]
11. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
Soneru IL; Agrawal L; Murphy JC; Lawrence AM; Abraira C
Diabetes Care; 1993 Jun; 16(6):896-901. PubMed ID: 8325203
[TBL] [Abstract][Full Text] [Related]
12. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE
Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
Yki-Järvinen H; Kauppinen-Mäkelin R; Tiikkainen M; Vähätalo M; Virtamo H; Nikkilä K; Tulokas T; Hulme S; Hardy K; McNulty S; Hänninen J; Levänen H; Lahdenperä S; Lehtonen R; Ryysy L
Diabetologia; 2006 Mar; 49(3):442-51. PubMed ID: 16456680
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
15. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
[TBL] [Abstract][Full Text] [Related]
16. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche A; Schweitzer MA; Häring HU;
Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
18. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
19. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
[TBL] [Abstract][Full Text] [Related]
20. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
Juntti-Berggren L; Pigon J; Karpe F; Hamsten A; Gutniak M; Vignati L; Efendic S
Diabetes Care; 1996 Nov; 19(11):1200-6. PubMed ID: 8908380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]